Kiromic BioPharma C-Suite Execs charged with misleading investors
The Securities and Exchange Commission settled charges against Houston-based Kiromic BioPharma, Inc., and two of its C-Suite executives for misleading investors about U.S. Food and Drug Administration...
Read More